Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Bone Marrow Transplant. 2019 May 15. doi: 10.1038/s41409-019-0451-2. [Epub ahead of print]

PMID:
31092900
2.

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Biol Blood Marrow Transplant. 2019 Mar;25(3):e76-e85. doi: 10.1016/j.bbmt.2018.12.068. Epub 2018 Dec 18.

PMID:
30576834
3.

Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.

Liu Y, Chen X, Han W, Zhang Y.

Drugs Today (Barc). 2017 Nov;53(11):597-608. doi: 10.1358/dot.2017.53.11.2725754. Review.

PMID:
29451276
4.

Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy.

Ittershagen S, Ericson S, Eldjerou L, Shojaee A, Bleickardt E, Patel M, Taran T, Anak O, Hall C, Leung M, Roccoberton D, Salmon F, Fuchs M, Romanov V, Lebwohl D.

Curr Hematol Malig Rep. 2019 Feb;14(1):47-55. doi: 10.1007/s11899-019-0498-6. Review.

PMID:
30666506
5.

Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia.

Thomas X, Paubelle E.

Expert Opin Biol Ther. 2018 Nov;18(11):1095-1106. doi: 10.1080/14712598.2018.1533951. Epub 2018 Oct 12. Review.

PMID:
30296188
6.
7.

CAR-T immunotherapy: how will it change treatment for acute lymphoblastic leukemia and beyond?

Capitini CM.

Expert Opin Orphan Drugs. 2018;6(10):563-566. doi: 10.1080/21678707.2018.1529562. Epub 2018 Oct 8.

PMID:
30775189
8.

CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.

Pehlivan KC, Duncan BB, Lee DW.

Curr Hematol Malig Rep. 2018 Oct;13(5):396-406. doi: 10.1007/s11899-018-0470-x. Review.

PMID:
30120708
9.

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL.

Lancet. 2015 Feb 7;385(9967):517-528. doi: 10.1016/S0140-6736(14)61403-3. Epub 2014 Oct 13.

PMID:
25319501
10.

Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy.

Subklewe M, von Bergwelt-Baildon M, Humpe A.

Transfus Med Hemother. 2019 Feb;46(1):15-24. doi: 10.1159/000496870. Epub 2019 Feb 5. Review.

11.

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia.

Zhao J, Song Y, Liu D.

J Hematol Oncol. 2019 Feb 14;12(1):17. doi: 10.1186/s13045-019-0705-x. Review.

12.

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia.

Vairy S, Garcia JL, Teira P, Bittencourt H.

Drug Des Devel Ther. 2018 Nov 12;12:3885-3898. doi: 10.2147/DDDT.S138765. eCollection 2018. Review.

13.

The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL.

Forsberg MH, Das A, Saha K, Capitini CM.

Ther Clin Risk Manag. 2018 Sep 3;14:1573-1584. doi: 10.2147/TCRM.S146309. eCollection 2018. Review.

14.

Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.

Luskin MR, DeAngelo DJ.

Curr Hematol Malig Rep. 2017 Aug;12(4):370-379. doi: 10.1007/s11899-017-0394-x. Review.

PMID:
28656487
15.

What CAR Will Win the CD19 Race?

Quintás-Cardama A.

Mol Cancer Ther. 2019 Mar;18(3):498-506. doi: 10.1158/1535-7163.MCT-18-1070. Review.

PMID:
30824581
16.

Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.

Cai B, Guo M, Wang Y, Zhang Y, Yang J, Guo Y, Dai H, Yu C, Sun Q, Qiao J, Hu K, Zuo H, Dong Z, Zhang Z, Feng M, Li B, Sun Y, Liu T, Liu Z, Wang Y, Huang Y, Yao B, Han W, Ai H.

J Hematol Oncol. 2016 Nov 25;9(1):131.

17.

CAR T-Cell Therapy: Update on the State of the Science.

Lamprecht M, Dansereau C.

Clin J Oncol Nurs. 2019 Apr 1;23(2):6-12. doi: 10.1188/19.CJON.S1.6-12.

PMID:
30880819
18.

Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.

Xiao W, Salem D, McCoy CS, Lee D, Shah NN, Stetler-Stevenson M, Yuan CM.

Cytometry B Clin Cytom. 2018 May;94(3):434-443. doi: 10.1002/cyto.b.21591. Epub 2017 Oct 31.

19.

American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States.

Mahmoudjafari Z, Hawks KG, Hsieh AA, Plesca D, Gatwood KS, Culos KA.

Biol Blood Marrow Transplant. 2019 Jan;25(1):26-33. doi: 10.1016/j.bbmt.2018.09.024. Epub 2018 Sep 26.

PMID:
30266675
20.

[Chimeric antigen receptors T cells in treatment of a relapsed pediatric acute lymphoblastic leukemia, relapse after allogenetic hematopoietic stem cell transplantation: case report and review of literature review].

Zuo Y, Wang J, Lu A, Jia Y, Wu J, Dong L, Chang L, Zhang L.

Zhonghua Xue Ye Xue Za Zhi. 2016 Feb;37(2):115-8. doi: 10.3760/cma.j.issn.0253-2727.2016.02.006. Review. Chinese.

PMID:
27014980

Supplemental Content

Support Center